Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to develop new Chimeric Antigen Receptor T-cell (CAR-T) targeted cell therapies…

Prescient Therapeutics has entered a collaboration with Carina Biotech to develop new targeted cell therapies for cancer patients with solid tumours. The collaboration will combine…

Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne. In this episode Tim chats with…

With a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX: PTX) develops personalised medicines as potential novel cancer remedies targeting an array of debilitating cancers with…

Prescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing personalised medicines as potential novel targeted cancer therapies for a range of challenging cancers with…

Shares of Mirati Therapeutics jumped after the company announced its first clinical cancer drug results. CNBC’s Meg Tirrell reports.

Growth investors willing to take the risk to shoot for the moon find prime targets in the biotechnology sector. The “holy grail” of growth investors…

The more prevalent role that algorithms, automation and data have on our day to day existence, mean that the everyday person is more cogent than…

Amgen’s never moved faster. In late August of last year, the first patient enrolled in a small clinical study received treatment with a cancer drug…